A001
19 Apr 2022
Trial Summary
A Phase 1, First-in-human Study of ARB202, Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies
Acronym:
A001
ACTRN/NCT /ethics:
NCT05411133
Scientific title:
Treatment of ARB202 Advanced Gastrointestinal Cancer Patients
Sponsor / Cooperative group:
Arbele Pty Ltd
Trial & Patient Characteristics
| Cancer Type | Gastrointestinal cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2022-05-30 |
| Anticipated End Date | 2025-08-01 |
Participating Hospitals
| Hospital | Southern Oncology Clinical Research Unit |
|---|---|
| Clinical Trial Coordinator | Meggan O'Riley |
| Meggan.ORiley@socru.org.au | |
| Phone | 0491 679 039 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Recruiting |